Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial - Audeh, M W; Carmichael, J; Penson, R T (Lancet, 2010)
et al.